That question matters because many pregnancies are unplanned, and women with diabetes may continue taking their medication before they know they are expecting. If a drug carries risks in pregnancy, that early exposure window becomes a serious concern.

What did the review find?

According to the researchers, using GLP-1 RA drugs for diabetes and weight management in women living with diabetes was not associated with adverse pregnancy outcomes in most cases. In plain terms, the pooled studies did not show a pattern of harm to the pregnancy in the majority of situations the analysis covered.

That is a reassuring signal for patients and clinicians, but it is not the final word. The authors themselves stress that evidence gaps remain. The available studies vary in design, population, and the specific drugs examined, and a meta-analysis cannot fill holes that the original studies leave open.

Why the caution?

Pregnancy research is notoriously difficult. Scientists cannot ethically run controlled trials in which pregnant women are deliberately assigned an experimental drug. As a result, evidence about medication safety in pregnancy usually accumulates slowly, from observational studies, registries, and retrospective analyses.

The new review suggests GLP-1 RAs are not linked to adverse outcomes in most cases, yet "in most cases" is not the same as "always safe." The remaining uncertainty means doctors will likely keep weighing the benefits of good blood sugar control against the still-incomplete safety picture for each individual patient.

What should patients take from this?

The findings offer cautious reassurance rather than a green light. Women with diabetes who are taking a GLP-1 drug and are pregnant or planning a pregnancy should discuss their medication with their healthcare provider rather than stopping or continuing it on their own. Suddenly discontinuing diabetes treatment carries its own well-documented risks to both mother and baby.

The full picture will emerge only as more data accumulate. Researchers in this field generally call for larger, longer-term studies that track pregnancies exposed to GLP-1 RAs, so that the remaining evidence gaps can close with actual data rather than assumption.

For now, the headline from Milan is measured: the best available pooled evidence does not show harm in most cases, and the scientific work of confirming that conclusion is still underway.